Resorptive drug use among comm unity-dwelling women in Minnesota

被引:3
作者
Farley, JF
Cline, RR
Hansen, RA
机构
[1] Univ Minnesota, Coll Pharm, Dept Pharmaceut Care & Hlth Syst, Minneapolis, MN 55455 USA
[2] Univ N Carolina, Coll Pharm, Div Pharmaceut Policy & Evaluat Sci, Chapel Hill, NC USA
关键词
age; ambulatory care; anticonvulsants; calcium; data collection; diuretics; drug use; estrogens; minerals; osteoporosis; steroids; cortico; toxicity; women;
D O I
10.1093/ajhp/61.15.1577
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The frequency of and factors associated with the use of resorptive medications among community-dwelling women age 45 years or older in Minnesota were studied. Methods. The study was a secondary analysis of a cross-sectional survey mailed to 1700 community-dwelling women age 45 years or older in Minnesota. The survey was designed to collect information about women's attitudes and beliefs regarding osteoporosis and antiresorptive medications. Respondents were also asked to give a detailed list of all prescription medications they currently used, including the quantity and directions for use. Descriptive statistics were calculated for the demographic, health, and medication-use characteristics of all respondents and for the subset of those using resorptive medications. Chi-square analysis and logistic regression were used to test bivariate and multivariate relationships. Results. Of the 990 usable surveys returned (adjusted response rate of 61.1%), 84 respondents (8.5%) reported using a resorptive drug. Age, health status, and the use of health care services (monthly physician visits and prescription use) were associated with resorptive drug use, controlling for other variables in the model. Women using resorptive medications were nearly 2.5 times more likely to report osteoporosis and osteopenia than women not using these medications. Conclusion. The use of resorptive medications in community-dwelling women in Minnesota was highest among those 75-84 years of age, women who were in poor health, and those frequently using health care services. These women were more likely to report using newer antiresorptive medications but were not more likely to use hormone therapy or calcium supplementation.
引用
收藏
页码:1577 / 1585
页数:9
相关论文
共 47 条
[1]   Corticosteroid-induced osteoporosis [J].
Adachi, JD .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 313 (01) :41-49
[2]  
Aday LA, 1997, HDB HLTH BEHAV RES, P153
[3]   Treatment of postmenopausal osteoporosis [J].
Altkorn, D ;
Vokes, T .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (11) :1415-1418
[4]   REVISITING THE BEHAVIORAL-MODEL AND ACCESS TO MEDICAL-CARE - DOES IT MATTER [J].
ANDERSEN, RM .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1995, 36 (01) :1-10
[5]  
[Anonymous], 2002, AM BON HLTH STAT OST, P1
[6]   Bone mineral density in women with asthma on long-term inhaled corticosteroid therapy [J].
Bonala, SB ;
Reddy, BM ;
Silverman, BA ;
Bassett, CW ;
Rao, YAK ;
Amara, S ;
Schneider, AT .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2000, 85 (06) :495-500
[7]  
Buckley LM, 1999, ARTHRITIS RHEUM, V42, P1736, DOI 10.1002/1529-0131(199908)42:8<1736::AID-ANR24>3.0.CO
[8]  
2-E
[9]   Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Bush, TL ;
Wells, HB ;
James, MK ;
BarrettConnor, E ;
Marcus, R ;
Greendale, G ;
Hunsberger, S ;
McGowan, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1389-1396
[10]   Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial [J].
Cauley, JA ;
Robbins, J ;
Chen, Z ;
Cummings, SR ;
Jackson, RD ;
LaCroix, AZ ;
LeBoff, M ;
Lewis, CE ;
McGowan, J ;
Neuner, J ;
Pettinger, M ;
Stefanick, ML ;
Wactawski-Wende, J ;
Watts, NB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1729-1738